HK inno.N Debuts in US$523 Million IPO and Listing on the Korea Exchange
Seoul – Paul Hastings LLP, a leading global law firm, announced today that it has advised HK inno.N Corporation on its US$523 million global offering and listing on the Korea Exchange. J.P. Morgan, Samsung Securities and Korea Investment & Securities acted as the lead underwriters.
HK inno.N is a leading biopharmaceutical and health & beauty care company in Korea with a broad portfolio of products, including K-CAB, a self-developed national blockbuster drug for treatment of gastrointestinal diseases. HK inno.N is the flagship pharmaceutical company of the HK Kolmar Group, a leading conglomerate in the fields of cosmetics, pharmaceuticals and health foods in Korea.
Paul Hastings’ leading Korea practice has advised on several landmark capital markets transactions in recent years, including KakaoBank’s US$2.2 billion Korea IPO, SK ie technology’s US$2 billion Korea IPO, Hanwha Systems’ US$345 million Korea IPO, Kakao Corp.’s US$1 billion GDR offering and ING Life Insurance Korea’s US$977 million IPO.
At Paul Hastings, our purpose is clear — to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.